Repurposed floxacins targeting RSK4 prevent chemoresistance and metastasis in lung and bladder cancer

• DOI: 10.1126/scitranslmed.aba4627
• Publication Date: 2021-07-14T19:16:26Z
• Authors: Stelios Chrysostomou; Rajat Roy; Filippo Prischi; Lucksamon Thamlik...; Kathryn L. Chapman; Uwais Mufti; Robert Peach; Laifeng Ding; David Hancock; Christopher Moore; Miriam Molina-Arcas; Francesco Mauri; David J. Pinato; Joel M. Abrahams; Silvia Ottaviani; Leandro Castellano; Georgios Giamas; Jennifer Pascoe; Devmini Moonamale; Sarah Pirrie; Claire Gaunt; Lucinda Billingham; Neil M. Steven; Michael Cullen; David Hrouda; Mathias Winkler; John Post; Philip Cohen; Seth J. Salpeter; Vered Bar; Adi Zundelevich; Shay Golan; Dan Leibovici; Romain Lara; David R. Klug; Sophia N. Yaliraki; Mauricio Barahona; Yulan Wang; Julian Downward; J. Mark Skehel; Maruf M.U. Ali; Michael J. Seckl; Olivier E. Pardo
• Keywords: Ex vivo

RSK4 promotes invasiveness and drug resistance in lung bladder cancer inhibition of this kinase shows therapeutic potential.